Introduction: There has been a progressive increase in the incidence of type II diabetes mellitus cases over the past decade. The availability of a wide variety of oral hypoglycemics has given rise to a number of adverse effects. In this case report, we describe the case of a patient recently diagnosed with type II diabetes. He was receiving treatment with glimepiride and experienced rapid onse...

BACKGROUND Oxidative stress due to improper control of blood glucose in chronic diabetes plays a major role in the development of secondary complications including cancer and birth defect. The aim of this study is to evaluate the protective effect of combination of pioglitazone with metformin or glimepiride against the experimental type-2 diabetes induced nuclear damage and reproductive toxicit...

Table 1. Relative effect sizes for change of HbA1c, risk of nausea and treatment discontinuation due to AEs, all GLP-1 RA treatments compared to placebo. • In addition to GLP-1 RAs, two sulfonylureas (glibenclamide, glimepiride), two thiazolidinediones (rosiglitazone, pioglitazone) the dipeptidyl peptidase-4 inhibitor sitagliptin and insulin were included to ensure a connected network of compar...

Introduction: Diabetes, a chronic disorder and requires life-long treatment. Cost of drug treatment is a major hurdle related to medication compliance in Type2 Diabetes Mellitus. Objective: To compare the cost and percentage price variation of single and combination therapy of oral hypoglycaemic agents across the different brands available in the Indian market. Methods: India’s medical research...

We investigated whether long-term glimepiride (GP) monotherapy improves insulin resistance and exerts a beneficial effect on beta cell function, as compared with glibenclamide (GC). One hundred Japanese Type 2 diabetic patients were randomly assigned to the GP (n = 50) or the GC (n = 50) group. During a 5-year monitoring period, patients received the indicated SU monotherapy, while changes in S...

BACKGROUND Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch. METHODS Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia....

The present investigation aimed to evaluate the protective effects of sitagliptin, glimepiride, rosuvastatin and their combinations on oxidative stress and endothelial dysfunction in the aortic tissues in fructose-fed type-2 diabetic rats. Sitagliptin (20 mg/kg, p.o.), glimepiride (2 mg/kg, p.o.), rosuvastatin (5 mg/kg, p.o.) and their combinations were administered for 6 w after induction of d...